Liang Cheng, President of International Society of Urological Pathology, Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared a post on LinkedIn:
“Congratulations to Drs. Zhenwei Zhang, Tahreem Karim, Kamaljeet Singh, Ruhul Quddus on the publication of this important study in Virchows Archiv Abbas Agaimy, MD – An important contribution to the evolving field of precision pathology!
Endometrial serous carcinoma (ESC) is one of the most aggressive forms of endometrial cancer. While HER2 overexpression has been recognized as an important biomarker in ESC, the prognostic significance of the combined expression of HER2, estrogen receptor (ER), and progesterone receptor (PR) has remained poorly understood.
In this study, we investigated the prognostic significance of combined HER2, estrogen receptor (ER), and progesterone receptor (PR) expression in endometrial serous carcinoma (ESC). We found that stratification based on HER2, ER, and PR status identifies clinically distinct subgroups with markedly different survival outcomes. Notably, both triple-positive (HER2+/ER+/PR+) and triple-negative (HER2-/ER-/PR-) tumors were associated with particularly poor overall survival and more aggressive clinicopathologic features.
Our study highlights substantial biological heterogeneity within ESC and suggests that combined receptor profiling may provide greater prognostic value than HER2 status alone. Our work lays the foundation for more refined risk stratification and supports the development of personalized therapeutic approaches for patients with this aggressive tumor.
Full article is available at the following link.
Free to read.”
Title: ER, PR, and HER2 triple positivity and triple negativity are associated with adverse prognostic significance in endometrial serous carcinoma
Authors: Zhenwei Zhang, Tahreem A. Karim, Liang Cheng, Kamaljeet Singh, M. Ruhul Quddus
Read the article here.
Other articles featuring Liang Cheng on OncoDaily.
